Concepts (219)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Multiple Sclerosis | 16 | 2023 | 174 | 2.920 |
Why?
|
| Multiple Sclerosis, Relapsing-Remitting | 9 | 2021 | 26 | 1.570 |
Why?
|
| Cerebellar Diseases | 1 | 2020 | 8 | 0.800 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2020 | 23 | 0.790 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2019 | 17 | 0.780 |
Why?
|
| Infectious Mononucleosis | 1 | 2020 | 36 | 0.780 |
Why?
|
| Intracranial Thrombosis | 1 | 2019 | 19 | 0.770 |
Why?
|
| Epstein-Barr Virus Infections | 1 | 2020 | 79 | 0.730 |
Why?
|
| Venous Thrombosis | 1 | 2019 | 104 | 0.710 |
Why?
|
| Dystonia | 1 | 2018 | 10 | 0.710 |
Why?
|
| Sjogren's Syndrome | 1 | 2018 | 24 | 0.690 |
Why?
|
| Antibodies, Monoclonal, Humanized | 4 | 2020 | 173 | 0.670 |
Why?
|
| Central Nervous System Diseases | 2 | 2016 | 44 | 0.590 |
Why?
|
| Immunosuppressive Agents | 4 | 2020 | 230 | 0.580 |
Why?
|
| Arthritis, Juvenile | 1 | 2015 | 5 | 0.580 |
Why?
|
| Etanercept | 1 | 2015 | 28 | 0.580 |
Why?
|
| Sarcoidosis | 1 | 2015 | 18 | 0.570 |
Why?
|
| Uveitis | 1 | 2015 | 18 | 0.570 |
Why?
|
| Multiple Sclerosis, Chronic Progressive | 3 | 2021 | 12 | 0.570 |
Why?
|
| Thrombocytopenia | 1 | 2014 | 48 | 0.510 |
Why?
|
| Olivary Nucleus | 1 | 2013 | 2 | 0.510 |
Why?
|
| Bipolar Disorder | 1 | 2016 | 244 | 0.510 |
Why?
|
| Cognition Disorders | 1 | 2015 | 205 | 0.500 |
Why?
|
| Central Nervous System Neoplasms | 1 | 2013 | 33 | 0.500 |
Why?
|
| Antirheumatic Agents | 1 | 2015 | 172 | 0.490 |
Why?
|
| Lymphoma | 1 | 2013 | 88 | 0.490 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2015 | 559 | 0.460 |
Why?
|
| Quality of Life | 1 | 2016 | 736 | 0.420 |
Why?
|
| Humans | 34 | 2023 | 49905 | 0.390 |
Why?
|
| Middle Aged | 17 | 2021 | 13562 | 0.340 |
Why?
|
| Male | 19 | 2021 | 23389 | 0.330 |
Why?
|
| Pyrimidines | 2 | 2019 | 102 | 0.330 |
Why?
|
| White Matter | 2 | 2019 | 82 | 0.320 |
Why?
|
| Vertebral Artery | 1 | 2006 | 17 | 0.300 |
Why?
|
| Diagnosis, Differential | 3 | 2019 | 753 | 0.300 |
Why?
|
| Adult | 14 | 2021 | 13399 | 0.300 |
Why?
|
| Biomedical Research | 2 | 2022 | 233 | 0.300 |
Why?
|
| Immunologic Factors | 3 | 2020 | 97 | 0.290 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2022 | 1374 | 0.290 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2006 | 121 | 0.290 |
Why?
|
| Female | 19 | 2021 | 26568 | 0.290 |
Why?
|
| Inflammation | 2 | 2019 | 971 | 0.220 |
Why?
|
| Cerebellum | 2 | 2019 | 81 | 0.210 |
Why?
|
| Biosensing Techniques | 1 | 2022 | 107 | 0.210 |
Why?
|
| Dimethyl Fumarate | 1 | 2020 | 7 | 0.210 |
Why?
|
| Crotonates | 1 | 2020 | 2 | 0.210 |
Why?
|
| Toluidines | 1 | 2020 | 2 | 0.210 |
Why?
|
| Phosphate-Binding Proteins | 1 | 2020 | 14 | 0.210 |
Why?
|
| Familial Mediterranean Fever | 1 | 2020 | 10 | 0.210 |
Why?
|
| Young Adult | 6 | 2020 | 3701 | 0.200 |
Why?
|
| Immunoglobulin G | 2 | 2020 | 420 | 0.200 |
Why?
|
| Pyroptosis | 1 | 2020 | 21 | 0.200 |
Why?
|
| Encephalomyelitis, Autoimmune, Experimental | 1 | 2020 | 48 | 0.200 |
Why?
|
| Immunoglobulin M | 1 | 2020 | 106 | 0.200 |
Why?
|
| Cysteine | 1 | 2020 | 100 | 0.190 |
Why?
|
| Positron-Emission Tomography | 2 | 2019 | 132 | 0.190 |
Why?
|
| Anticonvulsants | 1 | 2019 | 80 | 0.190 |
Why?
|
| Seizures | 1 | 2019 | 81 | 0.180 |
Why?
|
| Movement | 1 | 2020 | 125 | 0.180 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2018 | 2 | 0.180 |
Why?
|
| Raynaud Disease | 1 | 2018 | 2 | 0.180 |
Why?
|
| Alcoholism | 1 | 2021 | 263 | 0.180 |
Why?
|
| Salivary Glands, Minor | 1 | 2018 | 2 | 0.180 |
Why?
|
| Primary Dysautonomias | 1 | 2018 | 5 | 0.180 |
Why?
|
| Syncope | 1 | 2018 | 24 | 0.180 |
Why?
|
| Sensation Disorders | 1 | 2018 | 16 | 0.180 |
Why?
|
| Neuralgia | 1 | 2018 | 16 | 0.180 |
Why?
|
| Antibodies, Antinuclear | 1 | 2018 | 34 | 0.180 |
Why?
|
| Neuroimaging | 1 | 2019 | 77 | 0.170 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2020 | 302 | 0.170 |
Why?
|
| Migraine Disorders | 1 | 2018 | 38 | 0.170 |
Why?
|
| Cohort Studies | 3 | 2020 | 2091 | 0.170 |
Why?
|
| Natalizumab | 2 | 2014 | 8 | 0.170 |
Why?
|
| Antibodies, Viral | 1 | 2020 | 318 | 0.170 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2023 | 645 | 0.170 |
Why?
|
| Cross-Sectional Studies | 3 | 2022 | 2105 | 0.170 |
Why?
|
| Fatal Outcome | 2 | 2016 | 97 | 0.160 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2014 | 50 | 0.160 |
Why?
|
| Rituximab | 2 | 2014 | 64 | 0.160 |
Why?
|
| Patient Care Planning | 1 | 2017 | 70 | 0.160 |
Why?
|
| Basigin | 1 | 2016 | 2 | 0.160 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 171 | 0.160 |
Why?
|
| Receptors, GABA | 1 | 2016 | 7 | 0.160 |
Why?
|
| Mothers | 1 | 2020 | 224 | 0.160 |
Why?
|
| Gray Matter | 1 | 2016 | 17 | 0.160 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 184 | 0.160 |
Why?
|
| Alemtuzumab | 3 | 2020 | 9 | 0.160 |
Why?
|
| Aged | 9 | 2020 | 10948 | 0.160 |
Why?
|
| Microglia | 1 | 2019 | 174 | 0.160 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2016 | 46 | 0.150 |
Why?
|
| Interview, Psychological | 1 | 2016 | 76 | 0.150 |
Why?
|
| Tertiary Care Centers | 1 | 2016 | 81 | 0.150 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2015 | 37 | 0.140 |
Why?
|
| Infliximab | 1 | 2015 | 44 | 0.140 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2015 | 29 | 0.140 |
Why?
|
| Patient Participation | 1 | 2017 | 183 | 0.140 |
Why?
|
| Comorbidity | 2 | 2016 | 1003 | 0.140 |
Why?
|
| Methotrexate | 1 | 2015 | 64 | 0.140 |
Why?
|
| Psychotic Disorders | 1 | 2016 | 136 | 0.140 |
Why?
|
| Interferon beta-1a | 3 | 2020 | 9 | 0.140 |
Why?
|
| Prevalence | 2 | 2016 | 1132 | 0.140 |
Why?
|
| DNA Mutational Analysis | 1 | 2015 | 180 | 0.140 |
Why?
|
| Body Fluids | 1 | 2014 | 20 | 0.140 |
Why?
|
| Methylprednisolone | 1 | 2014 | 21 | 0.130 |
Why?
|
| Research Report | 1 | 2014 | 20 | 0.130 |
Why?
|
| Glycogen Debranching Enzyme System | 1 | 2014 | 2 | 0.130 |
Why?
|
| Glycogen Storage Disease Type IV | 1 | 2014 | 2 | 0.130 |
Why?
|
| Self Report | 1 | 2016 | 322 | 0.130 |
Why?
|
| Decision Making | 1 | 2017 | 319 | 0.130 |
Why?
|
| Prednisone | 1 | 2014 | 73 | 0.130 |
Why?
|
| Neuronal Plasticity | 1 | 2015 | 110 | 0.130 |
Why?
|
| Brain Neoplasms | 1 | 2016 | 229 | 0.130 |
Why?
|
| Hypertrophy | 1 | 2013 | 24 | 0.130 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 249 | 0.130 |
Why?
|
| Health Personnel | 1 | 2017 | 312 | 0.130 |
Why?
|
| Nervous System Diseases | 1 | 2014 | 82 | 0.130 |
Why?
|
| Nucleosomes | 1 | 2015 | 181 | 0.120 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2014 | 125 | 0.120 |
Why?
|
| Muscle Weakness | 1 | 2012 | 24 | 0.120 |
Why?
|
| Muscular Atrophy, Spinal | 1 | 2012 | 16 | 0.120 |
Why?
|
| Brain | 2 | 2022 | 1178 | 0.120 |
Why?
|
| Histones | 1 | 2015 | 439 | 0.110 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2015 | 602 | 0.110 |
Why?
|
| Treatment Outcome | 2 | 2020 | 3891 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 1 | 2014 | 595 | 0.100 |
Why?
|
| Chromatin | 1 | 2015 | 548 | 0.100 |
Why?
|
| Neurons | 1 | 2015 | 773 | 0.100 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2023 | 239 | 0.090 |
Why?
|
| Recurrence | 2 | 2023 | 500 | 0.090 |
Why?
|
| Depressive Disorder, Major | 1 | 2011 | 243 | 0.080 |
Why?
|
| Multimodal Imaging | 2 | 2019 | 53 | 0.080 |
Why?
|
| Follow-Up Studies | 3 | 2020 | 1950 | 0.080 |
Why?
|
| Incidental Findings | 1 | 2006 | 37 | 0.080 |
Why?
|
| Case-Control Studies | 2 | 2020 | 910 | 0.070 |
Why?
|
| HIV Infections | 1 | 2012 | 898 | 0.070 |
Why?
|
| Child | 3 | 2020 | 3831 | 0.070 |
Why?
|
| Contrast Media | 1 | 2006 | 291 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2016 | 439 | 0.070 |
Why?
|
| Aged, 80 and over | 2 | 2020 | 4241 | 0.070 |
Why?
|
| Interferon-beta | 2 | 2014 | 77 | 0.060 |
Why?
|
| Antigens, CD20 | 1 | 2023 | 11 | 0.060 |
Why?
|
| Plasma | 1 | 2022 | 34 | 0.060 |
Why?
|
| Metabolome | 1 | 2022 | 23 | 0.060 |
Why?
|
| Albumins | 1 | 2022 | 28 | 0.060 |
Why?
|
| Social Class | 1 | 2021 | 109 | 0.050 |
Why?
|
| Biomarkers | 2 | 2016 | 998 | 0.050 |
Why?
|
| Citric Acid Cycle | 1 | 2020 | 20 | 0.050 |
Why?
|
| Flow Cytometry | 1 | 2023 | 654 | 0.050 |
Why?
|
| Hydroxybutyrates | 1 | 2020 | 8 | 0.050 |
Why?
|
| T-Lymphocytes | 2 | 2016 | 912 | 0.050 |
Why?
|
| Nitriles | 1 | 2020 | 56 | 0.050 |
Why?
|
| Lower Extremity | 1 | 2021 | 113 | 0.050 |
Why?
|
| Anthropometry | 1 | 2020 | 76 | 0.050 |
Why?
|
| Hand | 1 | 2020 | 47 | 0.050 |
Why?
|
| Macrophage Activation | 1 | 2020 | 114 | 0.050 |
Why?
|
| Foot | 1 | 2020 | 36 | 0.050 |
Why?
|
| Mice, Mutant Strains | 1 | 2020 | 306 | 0.050 |
Why?
|
| Severity of Illness Index | 2 | 2016 | 1156 | 0.050 |
Why?
|
| Disease Progression | 2 | 2014 | 719 | 0.050 |
Why?
|
| Caspases | 1 | 2020 | 156 | 0.050 |
Why?
|
| Walking | 1 | 2021 | 181 | 0.050 |
Why?
|
| Mental Health | 1 | 2021 | 286 | 0.050 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2020 | 241 | 0.040 |
Why?
|
| Retrospective Studies | 2 | 2022 | 4520 | 0.040 |
Why?
|
| HEK293 Cells | 1 | 2020 | 526 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 149 | 0.040 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2021 | 410 | 0.040 |
Why?
|
| Lipopolysaccharides | 1 | 2020 | 638 | 0.040 |
Why?
|
| Patient Preference | 1 | 2017 | 65 | 0.040 |
Why?
|
| Inflammasomes | 1 | 2020 | 281 | 0.040 |
Why?
|
| CD28 Antigens | 1 | 2016 | 40 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 101 | 0.040 |
Why?
|
| Cluster Analysis | 1 | 2017 | 241 | 0.040 |
Why?
|
| Logistic Models | 1 | 2020 | 1168 | 0.040 |
Why?
|
| Focus Groups | 1 | 2017 | 265 | 0.040 |
Why?
|
| Pandemics | 1 | 2020 | 426 | 0.040 |
Why?
|
| Antibodies | 1 | 2016 | 161 | 0.040 |
Why?
|
| Adolescent | 2 | 2016 | 5398 | 0.040 |
Why?
|
| Infant | 1 | 2020 | 1385 | 0.040 |
Why?
|
| Multigene Family | 1 | 2015 | 95 | 0.040 |
Why?
|
| Frontal Lobe | 1 | 2015 | 60 | 0.040 |
Why?
|
| Fetus | 1 | 2015 | 101 | 0.030 |
Why?
|
| Mice | 2 | 2020 | 9199 | 0.030 |
Why?
|
| Animals | 3 | 2020 | 18003 | 0.030 |
Why?
|
| Socioeconomic Factors | 1 | 2017 | 752 | 0.030 |
Why?
|
| Macrophages | 1 | 2020 | 921 | 0.030 |
Why?
|
| Patient-Centered Care | 1 | 2017 | 221 | 0.030 |
Why?
|
| JC Virus | 1 | 2014 | 23 | 0.030 |
Why?
|
| Polyomavirus Infections | 1 | 2014 | 46 | 0.030 |
Why?
|
| Genetic Carrier Screening | 1 | 2014 | 15 | 0.030 |
Why?
|
| Leukoencephalopathies | 1 | 2014 | 16 | 0.030 |
Why?
|
| Hippocampus | 1 | 2015 | 184 | 0.030 |
Why?
|
| Spinocerebellar Ataxias | 1 | 2014 | 11 | 0.030 |
Why?
|
| Homozygote | 1 | 2014 | 115 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2014 | 144 | 0.030 |
Why?
|
| Lymphocyte Activation | 1 | 2016 | 731 | 0.030 |
Why?
|
| Age of Onset | 1 | 2014 | 163 | 0.030 |
Why?
|
| Mice, Inbred C57BL | 1 | 2020 | 2918 | 0.030 |
Why?
|
| DNA, Viral | 1 | 2014 | 241 | 0.030 |
Why?
|
| Riluzole | 1 | 2012 | 5 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2020 | 2558 | 0.030 |
Why?
|
| Occupational Therapy | 1 | 2012 | 12 | 0.030 |
Why?
|
| Arm | 1 | 2012 | 38 | 0.030 |
Why?
|
| Pregnancy | 1 | 2020 | 2093 | 0.030 |
Why?
|
| Physical Therapy Modalities | 1 | 2012 | 31 | 0.030 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2012 | 103 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2015 | 968 | 0.030 |
Why?
|
| Neuroprotective Agents | 1 | 2012 | 57 | 0.030 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 317 | 0.030 |
Why?
|
| Interferon-gamma | 1 | 2014 | 543 | 0.030 |
Why?
|
| Viral Load | 1 | 2012 | 232 | 0.030 |
Why?
|
| Acute Disease | 1 | 2014 | 606 | 0.030 |
Why?
|
| Amyotrophic Lateral Sclerosis | 1 | 2016 | 431 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2015 | 855 | 0.030 |
Why?
|
| Child, Preschool | 1 | 2015 | 1723 | 0.020 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 2011 | 386 | 0.020 |
Why?
|
| United States | 1 | 2020 | 6281 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2014 | 1589 | 0.020 |
Why?
|
| Time Factors | 1 | 2014 | 3184 | 0.020 |
Why?
|